Metabolic Research

Retatrutide
Triple-receptor agonist studied in preclinical and clinical literature for energy balance and metabolic homeostasis.
10 mg20 mg30 mg40 mg
View details →
Research blend - Tirzepatide 40 mg + Retatrutide 20 mg
Research blend pairing two incretin-class analogs for parallel-pathway laboratory study.
For laboratory research use only. Not for human, veterinary, diagnostic, cosmetic, or therapeutic use. Not evaluated by the FDA.